Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4178256 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4178256 Part A: Single-Ascending Dose (SAD) (Cohorts 1-6b) | EXPERIMENTAL | LY4178256 or Placebo administered Intravenously (IV) |
| LY4178256 Part B: Multiple Ascending Dose (MAD) (Cohorts 1-3) | EXPERIMENTAL | LY4178256 or Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4178256 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, and other screening procedures. * Have a body mass index within the range of 19.0 to 32.0 kilograms per square meter (kg/m²) * Individuals assigned male at birth willing to...
LY4178256 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied to evaluate its safety, tolerability, and pharmacokinetics in a clinical trial setting.
LY4178256 is being studied for use in healthy volunteers. The ongoing Phase 1 trial aims to assess the drug's safety, tolerability, and how it is processed by the body. It is not yet approved for any medical condition and remains in early-stage clinical development.
LY4178256 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants.
LY4178256 is in Phase 1 clinical development. The drug is currently being studied in a Phase 1 trial that is recruiting participants. It is an investigational drug and has not been approved by regulatory authorities for any use.
LY4178256 is being studied in a Phase 1 clinical trial with the identifier NCT07698210. This trial is titled 'A Study of LY4178256 in Healthy Participants' and is currently recruiting in the United States. The study is randomized, double-blind, and controlled, with an enrollment of 88 participants.